CN Patent

CN111217792B — 一种来那度胺b晶型的制备方法

Assigned to Cinkate Pharm Tech (shanghai) Co ltd · Expires 2021-09-28 · 5y expired

What this patent protects

本发明提供一种来那度胺B晶型的制备方法。具体地，本发明提供的方法包括步骤：(1)使原料来那度胺溶解于醇中，得到含来那度胺的溶液；和(2)向步骤(1)得到的含来那度胺的溶液中加入水，析晶得到来那度胺B晶型；其中，所述的醇选自下组：1,3‑丙二醇、1,2‑丙二醇，或其组合。本发明方法具有高稳定性和可靠性。

USPTO Abstract

本发明提供一种来那度胺B晶型的制备方法。具体地，本发明提供的方法包括步骤：(1)使原料来那度胺溶解于醇中，得到含来那度胺的溶液；和(2)向步骤(1)得到的含来那度胺的溶液中加入水，析晶得到来那度胺B晶型；其中，所述的醇选自下组：1,3‑丙二醇、1,2‑丙二醇，或其组合。本发明方法具有高稳定性和可靠性。

Drugs covered by this patent

Revlimid (lenalidomide) · Bristol-Myers Squibb

Patent Metadata

Patent number: CN111217792B
Jurisdiction: CN
Classification: —
Expires: 2021-09-28
Drug substance claim: No
Drug product claim: No
Assignee: Cinkate Pharm Tech (shanghai) Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.